How do you calculate batch yield and reconcile materials and labels, and when must a discrepancy be investigated?

1How yield is defined and calculated.

FDA defines three quantities. Theoretical yield is what “would be produced at any appropriate phase” based on the components used, “in the absence of any loss or error in actual production”. Actual yield is what is actually produced at that phase. Percentage of theoretical yield is the ratio of the two at the same phase, “stated as a percentage”.¹

Percentage of theoretical yield = actual yield ÷ theoretical yield × 100

If a compression step charged with enough granulate for 100,000 tablets produces 97,400 tablets, the percentage of theoretical yield at that phase is 97.4%.

Under 21 CFR 211.103, actual yields and percentages of theoretical yield “shall be determined at the conclusion of each appropriate phase” of manufacturing, processing, packaging or holding. One person calculates and a second independently verifies; if automated equipment calculates the yield, one person verifies it.² The batch record states the actual yield and the percentage of theoretical yield at those phases, under 211.188(b)(7).² EU GMP asks the batch processing record to show “the product yield obtained at different and pertinent stages of manufacture”.³

For active substances, ICH Q7 asks for actual yields to be compared with expected yields at designated steps, defining expected yield as the quantity or percentage of theoretical yield anticipated at a phase “based on previous laboratory, pilot scale, or manufacturing data”.⁴

2Where the limits come from.

Part 211 does not set a percentage. It requires each master production and control record to include “a statement of theoretical yield, including the maximum and minimum percentages of theoretical yield beyond which investigation according to § 211.192 is required”.² ICH Q7 likewise asks for expected yields “with appropriate ranges” established from earlier data.⁴

FDA’s CGMP questions and answers address processes with high but consistent losses. Asked about processes such as transdermal patches with high in-process reject rates, FDA said lower yields are not of themselves a concern, but “validated and well-controlled processes will achieve fairly consistent waste amounts batch-to-batch”, and waste above normal operating rates may need evaluating for its cause and its consequences for product quality.⁵

3How materials and labels are reconciled.

A reconciliation compares what was issued to a batch with what can be accounted for. Part 211 requires, for each component, an inventory record with “a reconciliation of the use of each lot”.² EU GMP Chapter 5 asks for “checks on yields, and reconciliation of quantities” to ensure there are no discrepancies outside acceptable limits.⁶ For packaging, the EU batch packaging record holds the quantities of printed packaging materials and bulk product “issued, used, destroyed or returned to stock and the quantities of obtained product, in order to provide for an adequate reconciliation”.³

Part 211 requires “strict control” over labelling issued for a batch. Section 211.125(c) requires procedures to “reconcile the quantities of labeling issued, used, and returned”, and evaluation of discrepancies between the quantity of finished product and the labelling issued “when such discrepancies are outside narrow preset limits based on historical operating data”. Those discrepancies are investigated under 211.192. Reconciliation is waived for cut or roll labelling only when electronic or electromechanical equipment examines 100 percent of units for correct labelling. Excess labelling bearing lot or control numbers is destroyed.² In the EU, unused batch-coded packaging materials are destroyed at the end of packaging and the destruction recorded.⁶

4When a discrepancy must be investigated.

Under 211.192, the quality control unit reviews and approves all production and control records, including packaging and labelling, before a batch is released. “Any unexplained discrepancy (including a percentage of theoretical yield exceeding the maximum or minimum percentages established in master production and control records)” must be thoroughly investigated, “whether or not the batch has already been distributed”. The investigation extends to other batches of the same product and to other products that may be associated with the discrepancy, and its written record includes the conclusions and follow-up.²

The wording covers both ends of the range: a yield above the maximum needs investigating as much as one below the minimum.

EU GMP sets the same expectation in its own terms. “Any significant deviation from the expected yield should be recorded and investigated”, and “any significant or unusual discrepancy” in reconciling bulk product, printed packaging materials and units produced “should be investigated and satisfactorily accounted for before release”.⁶ For active substances, ICH Q7 asks for deviations in yield associated with critical process steps to be investigated for their impact on the quality of affected batches.⁴

5How it runs in Seal.

In Seal, a batch material reconciliation compares the issued quantity with evidenced consumption, returns, samples and waste on the same quantity basis, and keeps an unexplained difference visible until evidence resolves it, as the worked example shows. Neil, Seal’s AI agent, can trace a material-balance discrepancy across ERP transactions, batch records and warehouse receipts into a source-linked report, and reconcile packaging components and labels so that unexplained labels remain visible before review. Neil does not create a loss entry or raise a reject count to make a balance close; your reviewers assess the discrepancy.

When yield falls, Neil can compare the runs with their parameters, timestamps and yields and draft an investigation with linked evidence and next checks. Your process owner assesses the explanations and decides what to test.